Aerie Pharmaceuticals to Announce Fourth Quarter & Full Year 2020 Financial Results & Host Conference Call on Thursday, Febru...
February 18 2021 - 07:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, ocular surface diseases and
retinal diseases, announced today that its fourth quarter and full
year 2020 financial results will be released after the market
closes on Thursday, February 25, 2021. Following the release, the
Company will host a live conference call and webcast at 5:00 p.m.
Eastern Time to discuss the Company’s financial results and provide
a general business update.
The live webcast and a replay may be accessed by visiting the
Company’s website at http://investors.aeriepharma.com. Please
connect to the Company’s website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call
(888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen
to the live conference call. The conference ID number for the live
call is 9047298. Please dial in approximately 10 minutes prior to
the call. Telephone replay will be available approximately two
hours after the call. To access the replay, please call (855)
859-2056 (U.S.) or (404) 537-3406 (international). The conference
ID number for the replay is 9047298. The telephone replay will be
available until March 5, 2021.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination
of Rhopressa® and the widely-prescribed PGA (prostaglandin analog)
latanoprost, was launched in the United States in May 2019. In
clinical trials of Rocklatan®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available at
www.rocklatan.com. Aerie continues to focus on global expansion and
the development of additional product candidates and technologies
in ophthalmology, including for wet age-related macular
degeneration and diabetic macular edema. More information is
available at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005018/en/
Media: Tad
Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami
Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2023 to Mar 2024